VeroScience

Biotechnology Research • Tiverton, Rhode Island, United States • 1-10 Employees

Company overview

Headquarters	1334 Main Road, Tiverton, Rhode Island 02878, US
Phone number	+14018160525
Website	veroscience.com
NAICS	541714
SIC	283
Employees	1-10
Socials

Key Contacts at VeroScience

Michael Ezrokhi

Director Of Therapeutics Development

Bindu Chamarthi

Medical Director

VeroScience Email Formats

VeroScience uses 2 email formats. The most common is {first initial}_{last name} (e.g., j_doe@veroscience.com), used 83.3% of the time.

Format	Example	Percentage
{first initial}_{last name}	j_doe@veroscience.com	83.3%
{first name}_{last name}	john_doe@veroscience.com	16.7%

About VeroScience

VeroScience is committed to developing novel, practical, and effective therapies for chronic debilitating human diseases such as Type 2 diabetes, metabolic syndrome, autoimmune disease, and cancer through interdisciplinary basic research. VeroScience researchers study biological clocks in vertebrates and their organizational influence on neuroendocrine regulation of physiology to develop new treatment strategies for metabolic and immune disorders. By investigating and mimicking nature’s means of regulating biochemical physiology for survival of vertebrates in the wild, VeroScience develops treatment strategies, not products per se, aimed at re-directing pathological biochemistry back towards its “normal” physiological organization. A major platform technology of the company is Circadian Neuroendocrine Resetting Therapy® that is utilized as a generator of multiple therapeutic strategies to treat a variety of disease states. The circadian timed daily (morning) administration of Cycloset®, a quick release formulation of bromocriptine mesylate (bromocriptine-QR), a dopamine agonist, was developed for the treatment of type 2 diabetes. Cycloset is approved by the U.S. FDA, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

VeroScience revenue & valuation

Annual revenue	$10,000,000
Revenue per employee	$1,250,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$32,000,000
Total funding	No funding